The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | CALR-targeted immunotherapy in myelofibrosis and ET: vaccine and antibody approaches
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses advances in calreticulin (CALR)-targeted immunotherapy, including vaccines, monoclonal antibodies, and bispecific antibodies, in myelofibrosis (MF) and essential thrombocythemia (ET). Dr Mascarenhas highlights that the mutant CALR antibody INCA033989 is effective and well tolerated in ET, demonstrating biomarkers of disease modification, and has also shown encouraging anemia responses in MF. With INCA033989 advancing to the Phase III EXCALIBUR-ET2 study (NCT07623200) in ET, and bispecific antibodies targeting mutant CALR in development, Dr Mascarenhas anticipates a future of biomarker-driven treatment. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
